Kymera Therapeutics (NASDAQ:KYMR) Insider Sells $723,100.00 in Stock

Kymera Therapeutics, Inc. (NASDAQ:KYMR) insider Noah Goodman sold 8,264 shares of the stock in a transaction on Thursday, April 9th. The shares were sold at an average price of $87.50, for a total value of $723,100.00. Following the sale, the insider owned 53,542 shares in the company, valued at $4,684,925. The trade was a 13.37% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Noah Goodman also recently made the following trade(s):

• On Friday, April 10th, Noah Goodman sold 2,000 shares of Kymera Therapeutics stock. The shares were sold at an average price of $87.35, for a total value of $174,700.00.

Kymera Therapeutics Stock Performance

NASDAQ:KYMR opened at $85.05 on Monday. The stock’s fifty day moving average is $82.95 and its 200 day moving average is $73.56. Kymera Therapeutics, Inc. has a fifty-two week low of $22.05 and a fifty-two week high of $103.00. The firm has a market capitalization of $6.94 billion, a PE ratio of -23.11 and a beta of 2.28.

Kymera Therapeutics (NASDAQ:KYMR) last released its quarterly earnings results on Thursday, February 26th. The company reported ($0.97) earnings per share for the quarter, missing the consensus estimate of ($0.77) by ($0.20). Kymera Therapeutics had a negative net margin of 794.04% and a negative return on equity of 28.71%. The company had revenue of $2.87 million for the quarter, compared to analysts’ expectations of $14.80 million. During the same quarter in the previous year, the company posted ($0.88) EPS. The business’s quarterly revenue was down 60.8% on a year-over-year basis. Equities analysts forecast that Kymera Therapeutics, Inc. will post -2.79 EPS for the current year.

Analyst Upgrades and Downgrades

KYMR has been the topic of several recent research reports. Weiss Ratings restated a “sell (d-)” rating on shares of Kymera Therapeutics in a report on Thursday, January 22nd. Wall Street Zen lowered Kymera Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, March 7th. Stephens increased their target price on Kymera Therapeutics from $95.00 to $100.00 and gave the stock an “overweight” rating in a research note on Monday, March 2nd. UBS Group increased their target price on Kymera Therapeutics from $90.00 to $128.00 and gave the stock a “buy” rating in a research note on Tuesday, March 3rd. Finally, Morgan Stanley reiterated an “overweight” rating and issued a $123.00 target price on shares of Kymera Therapeutics in a research note on Thursday, February 26th. One equities research analyst has rated the stock with a Strong Buy rating, twenty have issued a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $118.90.

Institutional Trading of Kymera Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the business. Smartleaf Asset Management LLC increased its stake in Kymera Therapeutics by 382.0% in the fourth quarter. Smartleaf Asset Management LLC now owns 535 shares of the company’s stock worth $42,000 after purchasing an additional 424 shares during the period. Larson Financial Group LLC increased its stake in Kymera Therapeutics by 81.5% in the third quarter. Larson Financial Group LLC now owns 777 shares of the company’s stock worth $44,000 after purchasing an additional 349 shares during the period. Caitong International Asset Management Co. Ltd purchased a new stake in Kymera Therapeutics in the fourth quarter worth $63,000. Bessemer Group Inc. increased its stake in shares of Kymera Therapeutics by 652.0% during the third quarter. Bessemer Group Inc. now owns 940 shares of the company’s stock valued at $53,000 after buying an additional 815 shares during the period. Finally, Osaic Holdings Inc. increased its stake in shares of Kymera Therapeutics by 18,050.0% during the second quarter. Osaic Holdings Inc. now owns 1,089 shares of the company’s stock valued at $48,000 after buying an additional 1,083 shares during the period.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.